Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's

This page shows the latest Parkinson's news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinsons drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial. Lundbeck’s acquisition of Pexton Pharma and its Parkinson’s disease candidate foliglurax has ended up being a bust, after the ... The AMBLED study did not show a statistically

Latest news

More from news
Approximately 41 fully matching, plus 228 partially matching documents found.

Latest Intelligence

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    That’s not dampening enthusiasm for the emerging field, however, and by some estimates, just about every big pharma company is active. ... C4 also has a collaboration in place with Biogen focusing on neurological conditions such as Alzheimer’s

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    Therapeutics to focus on therapies for Parkinson’s, epilepsy and other central nervous system disorders. ... It will be important to use ever-more sophisticated data sets to continue to understand pharma’s ongoing evolution.

  • Case study: What we're made of Case study: What we're made of

    This empathetic approach has provided a halo effect for Fresenius Kabi’s reputation, as well as improving Thick &Easy Clear sales. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple sclerosis, learning

  • Novel endpoints in the digital age Novel endpoints in the digital age

    Tenaerts cited a CTTI case study outlining the case for developing novel endpoints generated using mobile technology in Parkinson’s disease (PD) as an example. ... Imagine a patient has an accelerometer that’s monitoring heart rate or blood pressure

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as Parkinson’s and Huntington’s disease. ... Examples of ongoing projects include two which target the immune system with an aim to halt nerve cell damage in

More from intelligence
Approximately 1 fully matching, plus 36 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

More from appointments
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest from PMHub

  • The ALS patient journey

    Nick Goldup:Well, if we start right at the beginning, for people that get diagnosed with ALS it’s a death sentence. ... That will be the start of ALS, but your doctor will want to rule out other things, for example, Parkinson’s disease or multiple

  • The growing clinical importance of patient-reported outcomes (PROs)

    For example, in a clinical trial conducted for Parkinson’s disease (PD), the effect of using Levodopa-sparing treatments on QoL was tested. ... overall QoL, as measured on a disease-specific PRO, the Parkinson’s Disease Questionnaire.

  • The dark side of direct-to-consumer genetic tests

    Who can blame them? If an email landed in your inbox that appeared to indicate you had an increased risk of cancer, Parkinson’s disease, Alzheimer’s disease, or any other

  • Love Your Heart: An Innovative Interactive Video Programme

    It’s astonishing how many people with RA don't know that their condition could be detrimental to their heart. ... such as Parkinson’s (127, 000) and Multiple Sclerosis (100, 000).

  • The power of the patient

    Matt has also had several articles published, most notably in Parkinson's Europe and Primary Care Today. ... He has also written a series of articles for Parkinson's UK in their Quarterly Journal.

More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics